Stevenage, UK, 23 September 2015.
NeRRe Therapeutics Ltd, a clinical stage company developing a portfolio of neurokinin (NK) receptor antagonists, is pleased to announce that Dr Mary Kerr1 is joining the company as CEO at the beginning of October. Mary has spent the majority of her career on the R&D/commercial interface in global strategy and regional operational roles at the pharmaceutical company GSK and predecessor companies, predominantly in the speciality and orphan drug areas. She has also been appointed an Operating Partner at Advent Life Sciences, one of NeRRe’s investors.
Prior to her appointment at NeRRe, Mary held a range of senior leadership roles for more than 20 years, most recently as Senior Vice President and Global Franchise Leader for GSK’s Immunoinflammation and Infectious Diseases portfolio. Before that she was a founding member in the executive team of ViiV Healthcare, the independent, HIV company that combines the HIV expertise of GSK, Pfizer Inc and Shionogi, where she led, revitalised and grew the business in Europe.
Dr Martin Edwards, Senior Partner of Novo Ventures and Chairman of NeRRe Therapeutics, said ‘At this critical stage of the company development, Mary is a great addition to the NeRRe Therapeutics team and I am delighted to welcome her. Her broad range of business skills and experience will provide invaluable direction to the company and the future development of its rich portfolio.’
Dr Mary Kerr, CEO, said:
‘The NeRRe portfolio, which is focused on neuro-modulation of hyperactive tachykinin systems, has the potential to have significant clinical benefit in a diverse range of chronic debilitating conditions which impact patient quality of life. I’m delighted to be joining such an exciting company; with our portfolio starting to generate clinical data shortly, we will be developing our strategy to optimise the value of our assets.”
1 Photograph available on request
For more information, please contact:
Dr Mary Kerr/ Dr Mike Trower
Tel: +44 (0) 1438 906960
About NeRRe Therapeutics
NeRRe Therapeutics was formed in December 2012 and is focussed on the development of a portfolio of NK receptor antagonists acquired from GlaxoSmithKline (GSK), which have therapeutic potential in a broad range of indications. The company has intimate knowledge of the transferred assets and the neurokinin receptor system field. In 2012 NeRRe Therapeutics raised £11.5 million ($18.4 million) in Series A financing from two leading European financial institutions, Novo A/S (www.novo.dk/ventures) and Advent Life Sciences (www.adventLS.com), who are represented by Dr Martin Edwards (Chairman) and Dr Kaasim Mahmood respectively on the company’s Board. NeRRe (www.nerretherapeutics.com) is based at the state-of-the-art Stevenage Bioscience Catalyst (www.stevenagecatalyst.com), the UK’s first open innovation bioscience campus.